Abstract 39P
Background
Prostate cancer (PCa) is one of the leading malignant diseases in men worldwide. The presence of myeloid-derived suppressor cells (PMN-MDSCs) is a critical contributor to a pro-tumorigenic microenvironment in advanced disease, where the neutrophil-lymphocyte ratio (NLR) is prognostic. However, their involvement in the early stages of PCa is still unclear.
Methods
Patients affected by localized prostate cancer and undergoing radical prostatectomy at the Urology Department of the University Hospital of Padua were enrolled in the study after signing informed consent. Blood and tumor samples from 79 patients were collected and immunostained for flow cytometry analysis. Disease risk groups were assigned according to EAU guidelines. Correlation between experimental data and clinical and anatomopathological features was done by logistic regression and Sperman’s correlation.
Results
No association between neutrophil counts and NLR with oncological outcome was found in a population of 79 patients with localized prostate cancer. However, a subset of circulating immature myeloid cells was found to be associated with higher disease risk groups (OR = 1.19 CI.95 (1.02, 1.38), p-value = 0.027). Of note, primary tumor lesions did not reveal a significant enrichment of the immune infiltrate and any association with clinical scores. Further analyses on defining a new potential circulating biomarker showed encouraging results. Gene expression analyses are ongoing.
Conclusions
Localized PCa is not associated with a higher circulating number of neutrophils and higher NLR compared with healthy subjects. However, further analyses of specific myeloid cell subsets are needed.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract